Sign in or create an account to add this stock to your watchlist.
About Corvus Pharmaceuticals (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520
Debt
Debt-to-Equity RatioN/A
Current Ratio13.69
Quick Ratio13.69
Price-To-Earnings
Trailing P/E Ratio-4.22
Forward P/E Ratio-3.99
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.70 per share
Price / Book2.44
Profitability
EPS (Most Recent Fiscal Year)($2.72)
Net Income$-55,660,000.00
Net MarginsN/A
Return on Equity-51.29%
Return on Assets-46.52%
Miscellaneous
Employees55
Outstanding Shares29,190,000
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals (NASDAQ:CRVS) announced its earnings results on Thursday, May, 3rd. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.11. View Corvus Pharmaceuticals' Earnings History.
What price target have analysts set for CRVS?
3 Wall Street analysts have issued 1 year price objectives for Corvus Pharmaceuticals' stock. Their predictions range from $14.00 to $26.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $20.00 in the next twelve months. View Analyst Ratings for Corvus Pharmaceuticals.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Uniqure (QURE), Epizyme (EPZM), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), Immuron (IMRN), Intra-Cellular Therapies (ITCI), Retrophin (RTRX), Mirati Therapeutics (MRTX), Apellis Pharmaceuticals (APLS), Revance Therapeutics (RVNC), Zai Lab (ZLAB), Alder BioPharmaceuticals (ALDR), Athenex (ATNX), TG Therapeutics (TGTX) and Dynavax Technologies (DVAX).
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller M.D., Co-Founder, Chairman, Chief Exec. Officer and Pres (Age 67)
- Dr. Peter A. Thompson, Co-Founder and Director (Age 58)
- Mr. Leiv Lea, CFO & Chief Bus. Officer (Age 64)
- Dr. Joseph J. Buggy Ph.D., Co-Founder and Strategic Advisor (Age 51)
- Mr. Daniel W. Hunt, Sr. VP & Chief Bus. Officer
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Has Corvus Pharmaceuticals been receiving favorable news coverage?
Media coverage about CRVS stock has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corvus Pharmaceuticals earned a coverage optimism score of 0.10 on Accern's scale. They also gave media coverage about the company an impact score of 46.73 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Corvus Pharmaceuticals' major shareholders?
Corvus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include
ORBIMED ADVISORS LLC
(20.47%),
ADAMS STREET PARTNERS LLC
(15.50%), Adams Street Partners LLC (11.22%), BVF Inc. IL (9.28%), BlackRock Inc. (3.50%) and Millennium Management LLC (2.07%). Company insiders that own Corvus Pharmaceuticals stock include Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.
Which major investors are selling Corvus Pharmaceuticals stock?
Which major investors are buying Corvus Pharmaceuticals stock?
CRVS stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Adams Street Partners LLC, Millennium Management LLC, Rock Springs Capital Management LP, Sphera Funds Management LTD., Dimensional Fund Advisors LP and BlackRock Inc.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Insider Buying and Selling for Corvus Pharmaceuticals.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $11.48.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $324.63 million. The company earns $-55,660,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Corvus Pharmaceuticals employs 55 workers across the globe.
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Corvus Pharmaceuticals in the last 12 months. Their average twelve-month price target is $20.00, suggesting that the stock has a possible upside of 74.22%. The high price target for CRVS is $26.00 and the low price target for CRVS is $14.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $20.00 | $20.00 | $21.6667 | $21.6667 |
| Price Target Upside: | 74.22% upside | 122.22% upside | 66.67% upside | 66.67% upside |
Corvus Pharmaceuticals (NASDAQ:CRVS) Consensus Price Target History
Corvus Pharmaceuticals (NASDAQ:CRVS) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Corvus Pharmaceuticals (NASDAQ:CRVS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Corvus Pharmaceuticals (NASDAQ CRVS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 39.50%
Institutional Ownership Percentage: 85.35%
Corvus Pharmaceuticals (NASDAQ CRVS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/12/2018 | Adams Street Partners Llc | Major Shareholder | Buy | 588,235 | $8.50 | $4,999,997.50 | 4,420,516 |  |
| 3/12/2018 | Richard A Md Miller | CEO | Buy | 100,000 | $8.50 | $850,000.00 | | |
| 11/20/2017 | Richard A Md Miller | CEO | Buy | 10,000 | $10.79 | $107,900.00 | | |
| 6/23/2017 | Holdings A/S Novo | Major Shareholder | Buy | 20,000 | $10.95 | $219,000.00 | 3,244,046 | |
| 6/13/2017 | Richard A Md Miller | Insider | Buy | 25,000 | $9.88 | $247,000.00 | | |
| 6/24/2016 | Orbimed Advisors Llc | Director | Buy | 1,000 | $12.98 | $12,980.00 | | |
| 6/21/2016 | Orbimed Advisors Llc | Director | Buy | 38,383 | $12.75 | $489,383.25 | | |
| 6/16/2016 | Orbimed Advisors Llc | Director | Buy | 20,000 | $12.35 | $247,000.00 | | |
| 6/10/2016 | Peter A Thompson | Director | Buy | 50,000 | $12.96 | $648,000.00 | | |
| 5/20/2016 | Orbimed Advisors Llc | Director | Buy | 4,716 | $13.09 | $61,732.44 | | |
| 5/19/2016 | Peter A Thompson | Director | Buy | 6,800 | $11.77 | $80,036.00 | | |
| 5/13/2016 | Richard A Md Miller | CEO | Buy | 30,300 | $10.00 | $303,000.00 | | |
| 5/12/2016 | A/S Novo | Major Shareholder | Buy | 70,000 | $10.00 | $700,000.00 | 3,224,046 | |
| 3/29/2016 | Adams Street Partners Llc | Major Shareholder | Buy | 200,000 | $15.00 | $3,000,000.00 | | |
| 3/29/2016 | Peter A Thompson | Director | Buy | 550,000 | $15.00 | $8,250,000.00 | | |
(Data available from 1/1/2013 forward)
Corvus Pharmaceuticals (NASDAQ CRVS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Corvus Pharmaceuticals (CRVS) to Post FY2018 Earnings of ($3.15) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - May 24 at 8:38 AM |
| Corvus Pharmaceuticals (CRVS) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - May 17 at 4:53 PM |
| Corvus Pharmaceuticals (CRVS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 17 at 3:28 AM |
| Corvus Pharmaceuticals (CRVS) Cut to Sell at ValuEngine
www.americanbankingnews.com - May 15 at 1:15 PM |
| Corvus Pharmaceuticals (CRVS) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 8:41 PM |
| Wedbush Research Analysts Raise Earnings Estimates for Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - May 10 at 7:08 AM |
| Zacks: Brokerages Anticipate Corvus Pharmaceuticals (CRVS) to Announce -$0.84 EPS
www.americanbankingnews.com - May 9 at 11:17 PM |
| Corvus Pharmaceuticals (CRVS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 7 at 9:30 PM |
| Zacks Investment Research Upgrades Corvus Pharmaceuticals (CRVS) to Buy
www.americanbankingnews.com - May 4 at 10:09 PM |
| Corvus Pharmaceuticals (CRVS) Announces Quarterly Earnings Results, Beats Estimates By $0.11 EPS
www.americanbankingnews.com - May 4 at 6:14 PM |
 | Corvus: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:33 AM |
| ValuEngine Upgrades Corvus Pharmaceuticals (CRVS) to "Hold"
www.americanbankingnews.com - May 3 at 8:24 PM |
| Corvus Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 3 at 4:16 PM |
 | 3 Things In Biotech, April 30: Another ADC, Another Breakthrough, Another Immunotherapy
seekingalpha.com - May 1 at 4:16 PM |
| Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer
finance.yahoo.com - April 26 at 9:26 AM |
| -$0.71 EPS Expected for Corvus Pharmaceuticals (CRVS) This Quarter
www.americanbankingnews.com - April 22 at 3:16 PM |
| Corvus Pharmaceuticals (CRVS) Earns "Outperform" Rating from Cowen
www.americanbankingnews.com - April 19 at 10:46 PM |
| Corvus Pharmaceuticals (CRVS) Price Target Cut to $17.00
www.americanbankingnews.com - April 19 at 10:46 PM |
| Analysts Expect Corvus Pharmaceuticals Inc (CRVS) to Post -$0.71 Earnings Per Share
www.americanbankingnews.com - April 5 at 3:17 PM |
| Corvus Pharmaceuticals (CRVS) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - April 5 at 2:03 PM |
| Corvus Pharmaceuticals Inc (CRVS) Short Interest Update
www.americanbankingnews.com - March 31 at 2:56 AM |
| ValuEngine Downgrades Corvus Pharmaceuticals (CRVS) to Strong Sell
www.americanbankingnews.com - March 25 at 7:32 PM |
| Corvus Pharmaceuticals Inc (CRVS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 1:44 AM |
| Brokerages Expect Corvus Pharmaceuticals Inc (CRVS) Will Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - March 19 at 3:14 PM |
| Critical Comparison: Corvus Pharmaceuticals (CRVS) and Achieve Life Sciences (ACHV)
www.americanbankingnews.com - March 15 at 3:14 AM |
| Corvus Pharmaceuticals Inc (CRVS) Major Shareholder Adams Street Partners Llc Acquires 588,235 Shares
www.americanbankingnews.com - March 13 at 4:21 PM |
| Insider Buying: Corvus Pharmaceuticals Inc (CRVS) CEO Buys 100,000 Shares of Stock
www.americanbankingnews.com - March 12 at 4:30 PM |
| Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
finance.yahoo.com - March 12 at 10:35 AM |
 | Corvus Pharma (CRVS) Prices 7.06M Offering of Common Stock at $8.50/Share
www.streetinsider.com - March 8 at 5:06 PM |
| Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 8 at 10:04 AM |
| Equities Analysts Offer Predictions for Corvus Pharmaceuticals Inc's Q1 2018 Earnings (CRVS)
www.americanbankingnews.com - March 8 at 6:28 AM |
| Corvus Pharmaceuticals (CRVS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 7 at 8:34 PM |
| Corvus Pharmaceuticals Inc (CRVS) Expected to Post FY2022 Earnings of ($2.21) Per Share
www.americanbankingnews.com - March 7 at 4:19 PM |
| FY2018 EPS Estimates for Corvus Pharmaceuticals Inc (CRVS) Lowered by Cantor Fitzgerald
www.americanbankingnews.com - March 7 at 11:48 AM |
| Corvus Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference 2018
finance.yahoo.com - March 6 at 9:31 AM |
| Corvus Pharmaceuticals (CRVS) Receives "Buy" Rating from Cowen
www.americanbankingnews.com - March 2 at 4:22 PM |
| Corvus Pharmaceuticals (CRVS) Issues Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - March 2 at 11:39 AM |
| Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 1 at 4:39 PM |
| Corvus Pharmaceuticals Inc (CRVS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 27 at 1:52 AM |
| Reviewing Prosensa (RNA) & Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - February 21 at 11:16 PM |
| Zacks: Brokerages Anticipate Corvus Pharmaceuticals Inc (CRVS) to Announce -$0.66 Earnings Per Share
www.americanbankingnews.com - February 13 at 7:16 PM |
| Corvus Pharmaceuticals Inc (CRVS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 1:34 AM |
| Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum
finance.yahoo.com - February 1 at 9:06 AM |
| Comparing AC Immune (ACIU) & Corvus Pharmaceuticals (CRVS)
www.americanbankingnews.com - January 12 at 7:04 PM |
| Corvus Pharmaceuticals Inc (CRVS) Expected to Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - January 10 at 9:16 PM |
| Corvus Pharmaceuticals (CRVS) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - January 5 at 7:02 PM |
| Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - December 7 at 5:28 PM |
| Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard A. Md Miller Buys 10,000 Shares
www.americanbankingnews.com - November 22 at 4:53 PM |
| Analysts Anticipate Corvus Pharmaceuticals, Inc. (CRVS) to Post -$0.66 EPS
www.americanbankingnews.com - November 19 at 7:14 PM |
 | Corvus Pharmaceuticals Is Now Oversold (CRVS)
www.thestreet.com - November 14 at 10:59 PM |
Corvus Pharmaceuticals (NASDAQ:CRVS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Corvus Pharmaceuticals (NASDAQ:CRVS) Income Statement, Balance Sheet and Cash Flow Statement
Corvus Pharmaceuticals (NASDAQ CRVS) Stock Chart for Saturday, May, 26, 2018
Loading chart…
